agbioproMar 15, 20201 min readAfter Kymera's raise, Nurix nabs $120M as it too hones in on clinical workSanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work.3 views0 commentsPost not marked as liked
Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work.